Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer’s disease

Pratishtha Chatterjee1,2, Henrik Zetterberg3,4,5,6, Kathryn Goozee1,2,7,8, Chai K. Lim1, Kelly R. Jacobs1, Nicholas J. Ashton3,10,11,12, Abdul Hye10,11, Steve Pedrini2, Hamid R. Sohrabi1,2,7,13, Tejal Shah1,2,13, Prita R. Asih1, Preeti Dave1,8, Kaikai Shen14, Kevin Taddei2,13, David B. Lovejoy1, Gilles J. Guillemin11, Kaj Blennow3,4,†, Ralph N. Martins1,2,7,9,13,15,16,*

Abstract

Background: Blood markers indicative of neurodegeneration (neurofilament light chain; NFL), Alzheimer’s disease amyloid pathology (amyloid-β; Aβ), and neuroinflammation (kynurenine pathway; KP metabolites) have been investigated independently in neurodegenerative diseases. However, the association of these markers of neurodegeneration and AD pathology with neuroinflammation has not been investigated previously. Therefore, the current study examined whether NFL and Aβ correlate with KP metabolites in elderly individuals to provide insight on the association between blood indicators of neurodegeneration and neuroinflammation.

Methods: Correlations between KP metabolites, measured using liquid chromatography and gas chromatography coupled with mass spectrometry, and plasma NFL and Aβ concentrations, measured using single molecule array (Simoa) assays, were investigated in elderly individuals aged 65–90 years, with normal global cognition (Mini-Mental State Examination Score ≥ 26) from the Kerr Anglican Retirement Village Initiative in Ageing Health cohort.

Results: A positive correlation between NFL and the kynurenine to tryptophan ratio (K/T) reflecting indoleamine 2, 3-dioxygenase activity was observed (r = .451, p < .0001). Positive correlations were also observed between NFL and kynurenine (r = .364, p < .0005), kynurenic acid (r = .384, p < .0001), 3-hydroxykynurenine (r = .246, p = .014), anthranilic acid (r = .311, p = .002), and quinolinic acid (r = .296, p = .003). Further, significant associations were observed between plasma Aβ40 and the K/T (r = .375, p < .0005), kynurenine (r = .374, p < .0005), kynurenic acid (r = .352, p < .0005), anthranilic acid (r = .381, p < .0005), and quinolinic acid (r = .352, p < .0005). Significant associations were also observed between plasma Aβ42 and the K/T ratio (r = .215, p = .034), kynurenic acid (r = .214, p = .035), anthranilic acid (r = .278, p = .006), and quinolinic acid (r = .224, p = .027) in the cohort. On stratifying participants based on their neocortical Aβ load (NAL) status, NFL correlated with KP metabolites irrespective of NAL status; however, associations between plasma Aβ and KP metabolites were only pronounced in individuals with high NAL while associations in individuals with low NAL were nearly absent.

(Continued on next page)
Introduction

Neurofilament light chain (NFL), an axonal cytoskeletal protein, is an emerging blood marker for neurodegenerative diseases, for review see [1]. Since neurodegenerative processes involve axonal damage resulting in the release of neuronal NFL into extracellular spaces with subsequent diffusion into the cerebrospinal fluid (CSF) and the blood, elevated CSF and blood NFL concentrations are now recognised as features of several neurodegenerative diseases [2–7], including Alzheimer’s disease (AD) [8].

Neurodegeneration is known to be associated with neuroinflammation [9], and the kynurenine pathway (KP) is strongly upregulated in neuroinflammatory conditions [10–13]. The KP is induced by the activation of the enzyme, indoleamine 2,3-dioxygenase (IDO1), resulting in the metabolism of tryptophan (TRP) to kynurenine (KYN). Following the formation of KYN, the enzyme kynurenine aminotransferase converts KYN to kynurenic acid (KA). Alternatively, the enzymes kynureninase and kynurenine 3-monoxygenase metabolise KYN to anthranilic acid (AA) and 3-hydroxykynurenine (3-HK), respectively. Further, AA and 3-HK get metabolised to 3-hydroxyanthranilic acid (3-HAA), which further converts to aminocarboxymuconic semialdehyde (ACMA). ACMA either generates picolinic acid (PA) via the enzyme 2-amino-3-carboxymuconatesemialdehyde decarboxylase or spontaneously gets converted to quinolinic acid (QA), a neurotoxin and precursor for the redox agent, nicotinamide adenine dinucleotide (Fig. 1) [14]. Several inflammatory molecules such as interferon-γ, tumour necrosis factor-α, toll-like receptor 4, and lipopolysaccharide activate IDO1 triggering the production of several neuroactive KP metabolites by most of the brain cells, i.e. microglia, astrocytes, neurons, and infiltrating macrophages [15].

Fig. 1 The kynurenine pathway schematic. Within the KP, tryptophan is metabolised to kynurenine (KYN) via the enzymes indoleamine 2,3-deoxygenase or tryptophan deoxygenase and formamidase. KYN gets converted to kynurenic acid (KA) via the enzyme kynurenine aminotransferase. KYN is also metabolised to anthranilic acid (AA) by the enzyme kynureninase and to 3-hydroxykynurenine (3-HK) by the enzyme kynurenine-3-monoxygenase. AA and 3-HK are metabolised to 3-hydroxyanthranilic acid (3-HAA). 3-HAA further converts to aminocarboxymuconic semialdehyde that spontaneously either converts to the neurotoxin, quinolinic acid, a substrate for the redox agent, NAD+ or is assisted by enzyme 2-amino-3-carboxymuconatesemialdehyde decarboxylase to generate picolinic acid.
Increasing evidence shows that the KP is triggered in several neurodegenerative diseases [10, 16–19]. Further, several studies including those from our laboratory also report associations between the KP metabolites and AD pathogenesis, from the preclinical stage prior to cognitive decline to the clinical stage [14, 20–23]. For instance, higher plasma KYN to TRP (K/T) ratios, reflecting higher IDO activity, have been observed within the different stages of AD pathogenesis [14, 24, 25]. Two relatively recent studies observed elevated plasma AA concentrations in preclinical AD and in individuals at risk to dementia [14, 26]. Additionally, a decline in serum KA [27] and increase in plasma QA [28] have been observed in individuals with mild cognitive impairment (MCI) and AD. While NFL and the KP have both independently been reported to be associated with neurodegenerative diseases as described above, the association between the neurodegenerative marker, NFL, and markers indicative of neuroinflammation, such as KP metabolites, has not been investigated previously. The current study therefore investigated whether an association between NFL and KP metabolites was present in cognitively normal elderly individuals to provide insight on the association between blood indicators of neurodegeneration and neuroinflammation. Further, the increasing emphasis of plasma amyloid-β (Aβ) as a potential marker for AD [29, 30] led us to also investigate the associations between KP metabolites and plasma Aβ 40 and 42 species within the current study. Additionally, participants within the current study were also categorised as those within the preclinical phase of AD, characterised by high neocortical Aβ load (NAL) assessed via positron emission tomography (PET), and those with no apparent risk to AD or low NAL, to separately evaluate the aforementioned associations in each group (high/low NAL) in order to assess whether these associations were specific to AD-related neuropathology.

Methods

Participants

Participants from the Kerr Anglican Retirement Village Initiative in Ageing Health (KARVIAH) cohort, at baseline, described previously [31], were utilised in the current study. Briefly, 134 volunteers met the set screening eligibility inclusion and exclusion criteria for the KARVIAH cohort. The inclusion criteria comprised an age range of 65–90 years, good general health, no known significant cerebral vascular disease, fluent in English, adequate/corrected vision and hearing to enable testing, and no objective cognitive impairment as screened by a Montreal Cognitive Assessment (MoCA; a 0–30 point test assessing cognitive domains including short-term recall, learning trials, delayed recall, visuospatial abilities, three-dimensional cube, trail making, fluency, abstraction, and attention) score ≥ 26. MoCA scores lying between 18 and 25 were assessed on a case by case basis by the study neuropsychologist following stratification of scores according to age and education [32]. The exclusion criteria comprised the diagnosis of dementia based on the revised criteria from the National Institute on Aging-Alzheimer’s Association [33], presence of acute functional psychiatric disorder (including lifetime history of schizophrenia or bipolar disorder), history of stroke, severe or extremely severe depression (based on the Depression Anxiety Stress Scales), and uncontrolled hypertension (systolic BP > 170 mmHg or diastolic BP > 100 mmHg).

The 105 participants who met the eligibility criteria underwent neuroimaging, neuropsychometric evaluation, and blood collection, while the remaining either withdrew or declined neuroimaging. Within these 105 participants, 100 participants were considered to have normal global cognition based on their Mini-Mental State Examination (a 0–30 point test used to screen cognitive impairment) score (MMSE ≥ 26) [34] and were included in the current study. Plasma NFL and KP concentrations were measured in all 100 participants with MMSE ≥ 26, while plasma Aβ 40 and 42 species were measured in 98 and 97 participants (95 common), respectively, of the 100 participants with MMSE ≥ 26. All volunteers provided written informed consent prior to participation, and the Bellberry Human Research Ethics Committee, Australia (reference no. 2012-09-1086), and the Macquarie University Human Research Ethics Committee, Australia, provided approval for the study (reference no. 5201701078).

Blood collection and APOE genotyping

All participants fasted for a minimum of 10 h overnight prior to blood withdrawal employing standard serological methods and processing of serum and plasma [35]. Apolipoprotein E (APOE) genotype was determined from purified genomic DNA extracted from 0.5 mL whole blood as previously described [35].

Measurement of plasma neurofilament light chain and amyloid-β concentrations

The ultra-sensitive single molecule array (Simoa, Quanterix) platform was employed to measure plasma NFL and Aβ concentrations [8, 36, 37]. Calibrators were run in duplicates while samples were diluted fourfold for NFL and Aβ42, and eightfold for Aβ40 and run in singlicates. Two quality control (QC) samples were run in duplicates at the beginning and end of each plate for NFL, wherein a QC sample with a concentration of 12.1 pg/mL had repeatability and intermediate precision of 20.2%, while for a QC sample with a concentration of 155.8 pg/mL, repeatability was 14.6% and intermediate precision was 14.9%. For Aβ40, a QC sample with a concentration of 219 pg/mL, repeatability was 6.9% and intermediate precision was 7.9%. For Aβ42, a QC sample
with a concentration of 12.9 pg/mL, repeatability was 2.4% and intermediate precision was 5.6%.

Measurement of serum kynurenine pathway metabolites
Serum samples were collected in 2015 and stored at −80°C until thawed for measurement of KP metabolites in 2017. Serum kynurenine metabolites were measured as described previously [14]. Briefly, analyses of tryptophan, KYN, 3-HK, 3-HAA, and AA were performed simultaneously with ultra-high-performance liquid chromatography (UHPLC) [11]. KA separation was carried out following injection (10 μL) onto a Poroshell RRHT C-18, 1.8 μm 2.1 × 100 mm column (Agilent Technologies, Inc., Santa Clara, CA) and quantified via fluorescence detection (excitation and emission wavelengths of 344 nm and 388 nm, respectively; retention time 1.5 min). A gradient method with 50 mM sodium acetate, 25 mM zinc acetate and 2.25% acetonitrile (eluents A) and 10% acetonitrile (eluents B) was employed, and separation was performed at 38°C with a flow rate of 0.75 mL/min. Separation achieved over 10 min comprised 100% eluent A for 3 min, 50% eluent A for 2 min, 0% eluent A for 2 min, and re-equilibration with 100% eluent A for 3 min. Data were analysed with the Agilent OpenLAB CDS ChemStation (Edition C.01.04).

Simultaneous analysis of picolinic acid and quinolinic acid was performed as described previously [38] with minor modifications using an Agilent 7890A gas chromatography (GC) system coupled with Agilent 5975 C mass spectrometry detector and Agilent 7693A autosampler (Agilent Technologies, Inc., Santa Clara, CA) with 1 μL of derivatized mixture. Separation of picolinic acid and quinolinic acid was achieved with a DB-5MS column, 0.25 μm film thickness, and 0.25 mm × 30 m capillary column (Agilent Technologies, Inc., Santa Clara, CA) within 7 min, but the assay run time was set for 12 min to prevent sample carryover. Picolinic acid and quinolinic acid concentrations were analysed using Agilent GC/MSD ChemStation software (Edition 02.02.1431) and interpolated from the established 6-point calibration curves based on the abundance count ratio of the metabolites to their corresponding deuterated internal standards within each standard and sample. The intra- and inter-assay CV was within the acceptable range (4–8% for UHPLC assays, 7–10% for GCMS assays) calculated from the repeated measures of the metabolite standards incorporated during the sequence run.

Cohort characteristics are presented in Table 1. The cohort was divided into low and high NFL groups or grouped according to NFL quartiles (Additional file 1: Table S1). On comparing the low NFL with the high NFL group, no significant differences were observed, except for the significantly higher frequency of APOE ε4 carriers within the high NFL group, which was expected given that carriage of the APOE ε4 allele is a known risk factor for AD and high NFL [41]. Higher age and lower MMSE scores were associated with higher NFL quartiles as expected [42]. No significant differences in education and NFL were observed between individuals categorized based on their plasma NFL concentrations. Additionally, no significant differences in gender or APOE ε4 carrier status were observed between individuals lying in the different NFL quartiles.

Correlation between NFL and KP metabolites in all participants
NFL was observed to have a positive correlation with the K/T ratio (r = .451, p < .0001). Positive correlations were also observed between NFL and KP metabolites, KYN (r = .364, p < .0005), KA (r = .384, p < .0001), 3-HK (r = .246, p = .014), AA (r = .311, p = .002), and QA (r = .296,
p = .003). Figure 2 presents correlations between NFL and KP metabolites. After adjusting for age, gender, and APOE ε4 status, all the above-mentioned associations between NFL and KP metabolites, except for 3-HK, continued to remain significant (Additional file 2: Table S2).

**Correlation between NFL and KP metabolites in participants with low NAL**

NFL positively correlated with the K/T ratio (r = .450, p < .0005) in the 65 participants with low NAL. Positive correlations were also observed between NFL and KP metabolites, KYN (r = .335, p = .006), KA (r = .348, p = .005), and AA (r = .278, p = .025). Figure 3 presents correlations between NFL and KP metabolites. After adjusting for age, gender, and APOE ε4 status, the above-mentioned associations between NFL and KP metabolites continued to remain significant (Additional file 2: Table S2).

**Correlation between NFL and KP metabolites in participants with high NAL**

NFL positively correlated with the K/T ratio (r = .436, p = .009) in the 35 participants with high NAL. Positive correlations were also observed between NFL and KP metabolites, KYN (r = .390, p = .020), KA (r = .428, p = .010), 3-HK (r = .411, p = .014), AA (r = .335, p = .049), and QA (r = .411, p = .014). Figure 3 presents correlations between NFL and KP metabolites. After adjusting for age, gender, and APOE ε4 status, KYN and KA remained significant (Additional file 2: Table S2).

**Correlation between plasma Aβ and KP metabolites in all participants**

Plasma Aβ40 positively correlated with the K/T ratio (r = .375, p < .0005). A positive correlation was also observed between Aβ40 and KP metabolites, KYN (r = .374, p < .0005), KA (r = .352, p < .0005), AA (r = .381, p < .0005), PA (r = .205, p = .042), and QA (r = .352, p < .0005). Figure 4 presents correlations between Aβ40 and KP metabolites. After adjusting for age, gender, and APOE ε4 status, all the above-mentioned associations between Aβ40 and KP metabolites, except for PA, continued to remain significant (Additional file 3: Table S3). Plasma Aβ42 positively correlated with the K/T ratio (r = .215, p = .034), KA (r = .214, p = .035), AA (r = .278, p = .006), and QA (r = .224, p = .027). Figure 4 presents correlations between Aβ42 and KP metabolites. After adjusting for age, gender, and APOE ε4 status, Aβ42 only continued to correlate significantly with KA and AA while a trend remained for QA (Additional file 4: Table S4). Furthermore, the plasma Aβ40/42 ratio correlated with KYN (r = .236, p = .024) after adjusting for age, gender, and APOE ε4 status.

**Correlation between plasma Aβ and KP metabolites in participants with low NAL**

Plasma Aβ40 positively correlated with AA (r = .255, p = .044) and PA (r = .307, p = .014) while plasma Aβ42 was not observed to correlate with any KP metabolite in low NAL (n = 63 for Aβ40, n = 65 for Aβ42) participants.

### Table 1 Cohort characteristics

|                          | All participants | Low NAL        | High NAL       | p     |
|--------------------------|------------------|----------------|----------------|-------|
| Gender (N, males/females)| 32/68            | 19/46          | 13/22          | .419  |
| Age (years)              | 78.18 ± 5.52     | 77.61 ± 5.55   | 79.22 ± 5.38   | .165  |
| APOE ε4 carriers (N, %)  | 21 (21)          | 5 (7.7)        | 16 (45.7)      | < .0001 |
| Education (years)        | 14.43 ± 3.26     | 14.84 ± 3.37   | 13.64 ± 2.91   | .078  |
| MMSE (score)             | 28.61 ± 1.14     | 28.50 ± 1.16   | 28.80 ± 1.10   | .225  |
| NAL (SUVR)               | 1.35 ± 0.31      | 1.15 ± 0.08    | 1.71 ± 0.26    | –     |
| Tryptophan (μM)          | 43.33 ± 7.72     | 42.87 ± 8.15   | 44.17 ± 6.87   | .350  |
| Kynurenine (μM)          | 2.23 ± 0.58      | 2.12 ± 0.52    | 2.41 ± 0.63    | < .05 |
| Kynurenine to tryptophan ratio (K/T) | 52.61 ± 15.44     | 50.73 ± 13.94   | 56.08 ± 17.58   | .121  |
| Kynurenic Acid (nM)      | 52.06 ± 27.44    | 49.71 ± 26.25  | 56.41 ± 29.40  | .238  |
| 3-Hydroxykynurenic acid (nM) | 119.45 ± 37.47  | 117.74 ± 34.73 | 122.60 ± 42.42 | .554  |
| 3-Hydroxyanthranilic acid (nM) | 22.63 ± 9.14  | 22.15 ± 9.25   | 23.50 ± 8.99   | .406  |
| Anthranilic acid (nM)    | 35.48 ± 19.79    | 31.40 ± 14.99  | 43.04 ± 25.02  | < .005 |
| Picolinic acid (nM)      | 109.38 ± 49.82   | 112.06 ± 56.25 | 104.40 ± 35.07 | .572  |
| Quinolinic acid (nM)     | 171.83 ± 74.48   | 169.76 ± 75.89 | 175.66 ± 72.71 | .689  |

Baseline characteristics including gender, age, APOE ε4 status, education, Mini-Mental State Examination (MMSE) scores, and neocortical amyloid-β load (NAL) represented by the standard uptake value ratio (SUVR) of ligand 18F-florbetaben assessed via positron emission tomography, in the neocortical region normalised with that in the cerebellum, have been compared between low NAL (SUVR < 1.35) and high NAL (SUVR ≥ 1.35) study participants. Chi-square tests or linear models were employed as appropriate. Data have been presented in mean ± SD unless otherwise mentioned. Kynurenine to tryptophan ratios for all participants were multiplied by 1000. All p values for the kynurenine pathway metabolites were obtained from variables transformed to the logarithmic scale for analyses to meet assumptions of the statistical test employed.
After adjusting for age, gender, and APOE ε4 status, only PA correlated with Aβ40 (Additional file 3: Table S3). Figure 5 presents correlations between Aβ40 and KP metabolites. The plasma Aβ40/42 ratio correlated with 3-HK (\( r = .255, p = .049 \)) after adjusting for age, gender, and APOE ε4 status.

**Correlation between plasma Aβ and KP metabolites in participants with high NAL**

Plasma Aβ40 positively correlated with the K/T ratio (\( r = .627, p < .0001 \)) in participants with high NAL. A positive correlation was also observed between Aβ40 and KP metabolites, KYN (\( r = .578, p < .0005 \)), KA (\( r = .503, p = .002 \)), AA (\( r = .482, p = .003 \)), and QA (\( r = .615, p < .0001 \)) \((n = 35\) for Aβ40). Figure 6 presents correlations between Aβ40 and KP metabolites. After adjusting for age, gender, and APOE ε4 status, all the above-mentioned associations between Aβ40 and KP metabolites continued to remain significant (Additional file 3: Table S3). Further, plasma Aβ42 positively correlated with the K/T ratio (\( r = .494, p = .004 \)), KYN (\( r = .467, p = .007 \)), KA (\( r = .387, p = .029 \)), AA (\( r = .576, p = .0006 \)), and QA (\( r = .539, p = .001 \)) \((n = 32\) for Aβ42).

**Discussion**

The current study investigated the association of the KP metabolites with two emerging blood biomarkers for AD, namely NFL and Aβ. NFL has widely been reported to increase with the severity of neurodegeneration and cognitive impairment, including that in AD [8, 42–44], while plasma Aβ has shown strong potential in reflecting brain Aβ burden showing approximately 90% accuracy [29, 30].

Within the current study, significant positive associations between KP metabolites and NFL were observed. Interestingly, the positive association between the K/T ratio and NFL also suggests a positive association
between IDO (the first-rate limiting enzyme of the KP) activity and NFL. Given that increased IDO activity has been observed in inflammatory conditions [25], the association observed between IDO activity (K/T ratio) and NFL within cognitively normal elderly individuals in the current study may further reflect an association between the extent of inflammation and the extent of underlying neurodegeneration. Interestingly, NFL correlated with the KP metabolites irrespective of the AD-related pathology (NAL)
status in cognitively normal elderly individuals that were at no apparent risk of AD and in those with preclinical AD, characterised by high NAL. These observations perhaps reflect previous observations of elevated NFL not being specifically associated with NAL pathology but rather being common to the extent of neurodegeneration [7, 8, 45, 46]. For example, Mattsson and colleagues reported no significant differences in plasma NFL concentrations between Aβ-negative and Aβ-positive (based on CSF Aβ42) control individuals [8]. Further, no significant differences were observed in CSF NFL concentrations between Aβ-negative and Aβ-positive individuals within the control, MCI, or AD groups [45].
Additionally, a study within the autosomal dominant form of AD reported that while the rate of change of serum NFL was significantly higher in mutation carriers compared to noncarriers, the positive association observed between the rate of change of serum NFL and rate of change of brain Aβ deposition did not reach significance [46]. Findings from our study are further supported by elevated blood (and CSF) NFL in primary tauopathies with no Aβ, such as progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy [7]. Together, these findings indicate that NFL concentrations are not driven by NAL and that blood NFL is primarily a marker of neurodegeneration, which likely resulted in the observation of NAL status-independent associations between KP metabolites and NFL.

NFL together with neurofilament medium chain and neurofilament heavy chain constitutes the three neurofilament isofoms. While the neurofilaments are synthesized in the cell body, it has been posited that they are phosphorylated after transportaion to the axon [47]. In neurodegenerative conditions, the phosphorylated forms of neurofilaments are observed in the cell body and the proximal region of the axon, when a disequilibrium in the phosphorylation-dephosphorylation balance of neurofilaments occurs, as opposed to the distal region of the axon, in normal conditions [48]. Interestingly, evidence shows that the KP metabolite, QA, can potentially disrupt the homeostasis of the neural cell cytoskeleton via aberrant phosphorylation, contributing to aberrant cell functioning and neurodegeneration [49].

QA has been reported to activate the N-methyl-D-aspartate (NMDA) receptor resulting in Ca²⁺ ion influx into the cells, activating phosphorylation enzymes and therefore resulting in phosphorylation of the cytoskeleton components [49]. An acute QA infusion in the striatum of 30-day-old rats stimulated NFL hyperphosphorylation within 30 min, associated with cAMP-dependent protein kinase A and protein kinase Ca2+/calmodulin-dependent protein kinase II activity, reflecting the vulnerability of both neuronal and astrocyte cytoskeleton to QA toxicity [49]. While these results show that QA is toxic to the cytoskeleton and may be associated with neurodegeneration, findings from the current study, most interestingly, suggest that other KP metabolites upstream to QA are also associated with the disruption of the neuronal cytoskeleton protein NFL. Whether the other KP metabolites are associated with plasma NFL via mechanisms similar to QA are yet to be investigated.

In contrast to the similar associations observed between KP metabolites and NFL in both low and high NAL groups, the association between KP metabolites and plasma Aβ varied between the two groups, wherein associations between KP metabolites and plasma Aβ were nearly absent (particularly with K/T that reflects IDO activity) in individuals at no apparent risk of AD (or low NAL) but were pronounced between KP metabolites and plasma Aβ in preclinical AD, characterised by high NAL. These observations may be attributed to the vicious nature of the relationship between blood and brain Aβ and KP metabolites in individuals with high NAL, as described in Fig. 7.

Further, since we observed an interaction effect of NAL and gender on the KP metabolites previously [14], we also investigated whether an interaction effect of plasma Aβ and gender was present on the KP metabolites in the current study. Interestingly, no interaction effect was observed between plasma Aβ (40 or 42) and gender on KP metabolites.

It is acknowledged that the current study has its limitations with regard to its relatively modest sample size. Interestingly, unlike the associations between KP metabolites and NFL, the association between KP metabolites and the two plasma Aβ species 40 and 42 was distinct between low NAL and high NAL groups. The association between KP metabolites and plasma Aβ could be dependent on NAL such that the strong correlations between plasma Aβ and KP metabolites in the high NAL group may suggest an association between Aβ metabolism and inflammation within amyloid-positive individuals. However, the low Aβ concentrations in the plasma in the low NAL group may also contribute to these observations, although the assay used to measure plasma Aβ in the current study is an ultra-sensitive assay. Further, while more sensitive assays may aid increase Aβ measurement accuracy, the current observations also require validation in an independent cohort.

**Conclusion**

The major findings of the study are that positive correlations exist between KP metabolites and plasma NFL and Aβ concentrations in elderly individuals, wherein the associations between KP metabolites and plasma NFL are NAL status independent, while the associations between KP metabolites and plasma Aβ species (40 and 42) were NAL status dependent. The peripheral concentrations of NFL, Aβ, and KP metabolites potentially reflect ongoing pathological processes in the brain. Plasma NFL levels reflect axonal cytoskeleton damage [51–53], and plasma Aβ has been shown to reflect brain Aβ deposition [29, 30], both of which contribute to neurodegeneration, while increased KP activity is indicative of neuroinflammation [16]. Since observations from the current study suggest that the association of neurodegeneration and amyloid pathology with neuroinflammation manifests in
the periphery, preventing cytoskeleton cytotoxicity by elevated KP metabolites in the periphery may have therapeutic potential. Therefore, further studies on the enzymes that catalyse the production of various KP metabolites and potential KP enzyme inhibitors as potential therapeutic agents need to be investigated [54].

Fig. 7 Possible mechanisms involved in the association between blood KP metabolites and Aβ in high NAL participants. Elevated blood kynurenine (KYN), anthranilic (AA), and 3-hydroxykynurenine (3-HK) concentrations in individuals with high neocortical amyloid-β load (NAL) [14] potentially have increased KYN, AA, and 3-HK concentrations in the brain, given that blood KYN, AA, and 3-HK concentrations account for ~60% of the brain pools of these metabolites, given their permeability to the blood-brain barrier [50]. This increase in the kynurenine pathway (KP) intermediate substrates could result in increased microglial activation which in turn can result in the secretion of inflammatory signalling molecules, which further trigger amyloid-β generation and immune responses, resulting in a vicious cycle. Further, immune responses such as interferon-γ activate indoleamine 2,3-dioxygenase result in increased tryptophan degradation and increased KP metabolites.

Additional files

Additional file 1: Table S1. Cohort characteristics based on neurofilament light chain quartiles. (DOCX 15 kb)
Additional file 2: Table S2. Correlation between KP metabolites and NFL in all participants and after stratifying by NAL status (low/high NAL), adjusting for age, gender and APOE ε4 status. (DOCX 16 kb)
Additional file 3: Table S3. Correlation between plasma KP metabolites and Aβ40 in all participants and after stratifying by NAL status (low/high NAL), adjusting for age, gender and APOE ε4 status. (DOCX 16 kb)
Additional file 4: Table S4. Correlation between plasma KP metabolites and Aβ42 in all participants and after stratifying by NAL status (low/high NAL), adjusting for age, gender and APOE ε4 status. (DOCX 18 kb)

Abbreviations
3-HAA: 3-Hydroxyanthranilic acid; 3-HK: 3-Hydroxykynurenine; AA: Anthranilic acid; ACMA: Aminocarboxymuconic semialdehyde; AD: Alzheimer’s disease; APOE: Apolipoprotein gene; Aβ: Amyloid-beta; CSF: Cerebrospinal fluid; GC: Gas chromatography; IDO: Indoleamine 2,3-dioxygenase; K/T: Kynurenine to tryptophan ratio; KA: Kynurenic acid; KARVIAH: Kerr Anglican Retirement Village Initiative in Ageing Health; KP: Kynurenine pathway; KYN: Kynurenine; MCI: Mild cognitive impairment; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; NAL: Neocortical amyloid-beta load; NFL: Neurofilament light chain; PA: Picolinic acid; PET: Positron emission tomography; QA: Quinolinic acid; QC: Quality control; Simoa: Single molecule array; SUVR: Standard uptake value ratio; TRP: Tryptophan; UHPLC: Ultra-high-performance liquid chromatography.

Acknowledgements
We thank the participants and their families for their participation and cooperation, and the Anglicare, KaRa MINDS, and AARF research and support staff for their contributions to this study. We also thank the staff of the Macquarie Medical Imaging centre in Macquarie University Hospital, Sydney, for their contributions. Florbetaben is a proprietary PET radiopharmaceutical owned by Primal Imaging SA. For this study, florbetaben was manufactured and supplied under GMP conditions by Cyclotek (Aust) Pty Ltd.

Authors’ contributions
PC and RNM conceived the idea, and PC wrote the manuscript. HZ and KB measured the plasma NFL and Aβ. CKL, KRI, DBJ, and GJG measured the serum KP metabolites. HZ, KG, CKL, KRI, NJA, AH, SP, HRS, TS, PRA, PD, KS, KT, DBJ, GJG, and KB, and RNM critically reviewed the manuscript. All authors read and approved the final manuscript.

Funding
This study was funded by the Anglicare, Sydney; the Australian Alzheimer’s Research Foundation (AARF), Perth; and the KaRa Institute of Neurological Diseases (KaRa MINDS), Sydney. HZ is a Wallenberg Academy Fellow supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), and the Swedish State Support for Clinical Research (#ALFGBG-720931). KG is a recipient of the Cooperative Research Centre for Mental Health top-up scholarship.
 Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All volunteers provided written informed consent prior to participation, and the Bellberry Human Research Ethics Committee, Australia (reference no. 2012-09-1086), and the Macquarie University Human Research Ethics Committee, Australia, provided approval for the study (reference no. 201701078).

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia. 2School of Medical Health and Sciences, Edith Cowan University, Joondalup, WA, Australia. 3Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden. 4Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. 5Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK. 6UK Dementia Research Institute at UCL, London, UK. 7KåRa Institute of Neurological Disease, Sydney, Macquarie Park, NSW, Australia. 8Clinical Research Department, Anglicare, Sydney, Castle Hill, NSW, Australia. 9School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, WA, Australia. 10Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, King’s College London, London, UK. 11NHRI Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia, South London and Maudsley NHS Foundation, London, UK. 12Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden. 13Australian Alzheimer’s Research Foundation, Nedlands, WA, Australia. 14Australian eHealth Research Institute, 8 Verdun Street, Nedlands, WA 6009, Australia.

Received: 10 May 2019 Accepted: 29 August 2019

Published online: 10 October 2019

References
1. Khall M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Combellaa M, Fazekas F, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577–89.
2. Badzioch DC, Eriksson Domellof M, Linder J, Olsson B, Ohrfelt A, Trupp M, et al. Increased neopterin production and kynurenine pathway abnormalities in preclinical Alzheimer disease patients. Adv Med Sci. 2010;55:204–10.
3. Li QX, Martins R, Rowe C, et al. High performance plasma amyloid-beta biomarker panels for preclinical Alzheimer disease. JAMA Neurol. 2017;74:1327.
4. Chatterjee P, Goozée K, Lim CK, James I, Shen K, Jacobs KR, Sohrabi HR, Shah T, Ash PR, Dave P, et al. Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-beta load: a pilot study. Sci Rep. 2018;8:8008.
5. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia. 2005;49:15–23.
6. Chouraki V, Preis SR, Yang Q, Beiser A, Li S, Larson MG, Weinstein G, Wang TJ, Gerszten RE, Vasan RS, Seshadri S. Kynurenine pathway abnormalities in Parkinson’s disease. Neurology. 1992;42:702–6.
7. Mancuso R, Hemis A, Agostini S, Rovaris M, Caputo D, Fuchs D, Clerici M. Indoleamine 2,3-dioxygenase (IDO) expression and activity in relapsing-remitting multiple sclerosis. PLoS One. 2015;10:e0137015.
8. Schwartz R, Brun J, Muchowski PJ, Wu HG. Kynurenines in the marmoset brain when physiology meets pathology. Nat Rev Neuosci. 2012;13:465–77.
9. Bonda DJ, Malankot M, Stone JK, Garrett MJ, Staniszewska M, Castellani RJ, et al. Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer’s disease. Redox Rep. 2010;15:161–8.
10. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer’s disease hippocampus. Neuropathol Appl Neurobiol. 2005;31:395–404.
11. Dezi L, Tuka B, Martsos D, Vecsei L. Alzheimer’s disease, astrocytes and kynurenines. Curr Alzheimer Res. 2015;12:462–80.
12. Greilberger J, Fuchs D, Leibhuber F, Greilberger M, Wintersteiger R, Tafet E. Carbonyl proteins as a clinical marker in Alzheimer’s disease and its relation to cytokinergic pathways and immune activation. J Neural Transm. 2010;117:6441–8.
13. Widner B, Leibhuber F, Walli J, Tafet E, Diemel U, Fuchs D. Tryptophan degradation and immune activation in Alzheimer’s disease. J Neuroinflamm. 2000;7:343–53.
14. Chouraki V, Preis S, Yang Q, Beiser A, Li S, Larson MG, Weinstein G, Wang TJ, Gerszten RE, Vasan RS, Sekhadi S. Association of amine biomarkers with incident dementia and Alzheimer’s disease in the Framingham Study. Alzheimers Dement. 2017;13:1327.
15. Hartiz J, Juhasz A, Rimondaco A, Janaky T, Donko T, Dux L, Penke B, Toth GK, Janika Z, Kalman J. Decreased serum and red blood cell kynurenine acid levels in Alzheimer’s disease. Neurochem Int. 2007;50:308–13.
16. Gulaj E, Pavlik K, Bien B, Pavlik D. Kynurenine and its metabolites in Alzheimer’s disease patients. Adv Med Sci. 2010;55:204–11.
17. Nakamura A, Kanieki N, Villermaine VL, Kato T, Doeeke J, Dore V, Fowler C, Li Q, Martins R, Rowe C, et al. High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature. 2018;554:24–9.
18. Ovod V, Ramsey KJ, Mawuenyea KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holmzann DM, Morris JC, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13:891–9.
19. Chouraki V, Chatterjee K, James I, Shen K, Sohrabi HR, Ash PR, Dave P, Ball B, ManYan C, Taddei K, et al. Alterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease. Sci Rep. 2017;7:6766.
20. Rossetti HC, Lacritz LH, Cullum CM, Weiner MF. Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology. 2011;77:1272–5.
33. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.

34. Folstein ME, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.

35. Gozee K, Chatterjee P, James I, Shen K, Sohrabi HR, Asih PR, Dave P, ManYan C, Taddei K, Ayton SJ, et al. Elevated plasma ferritin in elderly individuals with high neocortical amyloid-β load. Mol Psychiatry. 2019;22:1807–12.

36. Rohrer JD, Woollacott IO, Dick KM, Brotherhood E, Gordon E, Fellows A, Toombs J, Duyveh R, Cardoso MJ, Ourselin S, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87:1329–36.

37. Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, Rohrer JD, Woollacott IO, Dick KM, Brotherhood E, Gordon E, Fellows A, Toombs J, Duyveh R, Cardoso MJ, Ourselin S, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87:1329–36.

38. Smythe GA, Braga O, Brew BJ, Grant RS, Guillemin GJ, Kerr SJ, Walker DW. Concurrent quantification of quinolinic, picolinic, and nicotinic acids using electron-capture negative-ion gas chromatography-mass spectrometry. Anal Biochem. 2002;301:21–6.

39. Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Macaulay SL, Armes D, Masters CL, Ellis KA, Villemagne VL, et al. MR-less surface-based amyloid deposition assessment based on 11C PiB PET. PLoS One. 2014;9:e84777.

40. Bourgeat P, Villemagne VL, Dore V, Brown B, Macaulay SL, Martins R, Masters CL, Armes D, Ellis K, Rowe CC, et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging. 2015;36(Suppl 1):S159–66.

41. Polvoksi T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkoniemi A, Niinisto L, Halonen P, Kontula K. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med. 1995;333:1242–7.

42. Chatterjee P, Gozee K, Sohrabi HR, Shen K, Shah T, Ash PR, Dave P, ManYan C, Taddei K, Chung R, et al. Association of plasma neurofilament light chain with neocortical amyloid-beta load and cognitive performance in cognitively normal elderly participants. J Alzheimers Dis. 2018;63:479–87.

43. Weston PSJ, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K, Duyveh R, Malone B, Ahsan RL, Pemberton H, et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology. 2017;89:2167–75.

44. Meeter LH, Dopper EG, Islaact LC, Sanchez-Valle R, Grif C, Benussi L, Ghidoni R, Preische O, Schultz SA, Apel A, Kuhle J, Leppert D, Petzold A, Bestwick JP, Malaspina A, Lu CH, Toombs J, Duyveh R, Cardoso MJ, Ourselin S, et al. Serum neurofilament light chain protein is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry. 2015;86:273–9.

45. Neselius S, Brisby H, Theodorsson A, Blennow K, Theodorsson A, Blennow K, Zetterberg H, Marcusson J. Concurrent quantification of quinolinic, picolinic, and nicotinic acids using electron-capture negative-ion gas chromatography-mass spectrometry. Anal Biochem. 2002;301:21–6.

46. Sheh TB, Chan WK, Kuthkuley J, Lee S. Organizational dynamics, functions, and pathobiological dysfunctions of neurofilaments. Results Probi Cell Differ. 2009;48:29–45.

47. Polvoksi T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkoniemi A, Niinisto L, Halonen P, Kontula K. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med. 1995;333:1242–7.

48. Preische O, Schultz SA, Apel A, Kuhle J, Leppert D, Petzold A, Bestwick JP, Malaspina A, Lu CH, Toombs J, Duyveh R, Cardoso MJ, Ourselin S, et al. Serum neurofilament light chain protein is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry. 2015;86:273–9.

49. Neselius S, Brisby H, Theodorsson A, Blennow K, Zetterberg H, Marcusson J. CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS One. 2012;7:e33606.

50. Kuhle J, Gaiottino J, Leppert D, Petzold A, Bestwick JP, Malaspina A, Lu CH, Dobson R, Disanto G, Norgren N, et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry. 2015;86:273–9.

51. Folstein ME, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.

52. Gozee K, Chatterjee P, James I, Shen K, Sohrabi HR, Asih PR, Dave P, ManYan C, Taddei K, Ayton SJ, et al. Elevated plasma ferritin in elderly individuals with high neocortical amyloid-β load. Mol Psychiatry. 2019;22:1807–12.

53. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005;233:183–98.

54. Zwingl D, Huang SY, Sathya S, Kovtunovych VM, Zolotarevsky E, Guidetti P, Wu H, Lee J, Truong J, Andrews-Zwilling Y, Hsieh E, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell. 2011;145:863–74.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.